Track SeaStar Medical Holding Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

SeaStar Medical Holding Corporation Common Stock ICU · Stock Open SeaStar Medical Holding Corporation Common Stock in new tab

0.8384 USD
EPS
-2.97
P/B
1.88
ROE
-356.87
Beta
-1.04
Target Price
10.00 USD
SeaStar Medical Holding Corporation Common Stock logo

SeaStar Medical Holding Corporation Common Stock

🧾 Earnings Recap – Q3 2026

SeaStar Medical shares fell 44.7% after earnings, with the clearest disappointment being a delay in the NEUTRALIZE-AKI trial: enrollment is now expected to finish by mid-2027. QUELIMMUNE sales grew sharply, but that progress was overshadowed by the slower timeline for the pivotal adult AKI study.

  • NEUTRALIZE-AKI has enrolled about 75% of its planned 339 patients; management now expects enrollment completion by mid-2027, citing strict eligibility criteria and a cautious outlook.
  • QUELIMMUNE revenue was over $630,000 in Q3, up 247% year over year. Nine-month revenue reached $1.7 million, and management expects to exceed its $2 million full-year revenue guidance.
  • Twenty of the 50 targeted pediatric medical centers are current customers; SeaStar has added 10 new customers so far in 2026.
  • The FDA confirmed SeaStar met requirements for the mandatory SAVE post-approval registry, and CMS assigned ICD-10-PCS codes for procedures using QUELIMMUNE.
  • SeaStar received FDA Breakthrough Device Designation for its SCD therapy for hyperinflammation in adults with sepsis and has submitted the first module of the adult AKI PMA.
📅
Loading chart...
Key Metrics
Earnings dateMarch 24, 2027
EPS-2.97
Book Value1.01
Price to Book1.88
Debt/Equity3.12
% Insiders11.623%
Growth
Revenue Growth0.82%
Estimates
Forward P/E-0.74
Forward EPS-2.57
Target Mean Price10.00

DCF valuation

Model fair value for SeaStar Medical Holding Corporation Common Stock (ICU)
Result
Sign in to run the valuation for ICU.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus None · mean target 10.00 USD (low 8.00, high 12.00) · as of 11 Nov 2026
Low 8.00
Mean 10.00
High 12.00
Price 0.8384
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

SeaStar Medical Holding Corporation Common Stock Logo SeaStar Medical Holding Corporation Common Stock Analysis (ICU)

United States Health Care Official Website Stock

Is SeaStar Medical Holding Corporation Common Stock a good investment? SeaStar Medical Holding Corporation Common Stock (ICU) is currently trading at 0.8384 USD. Market analysts have a consensus price target of 10.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: SeaStar Medical Holding Corporation Common Stock is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -2.57.

Investor FAQ

Does SeaStar Medical Holding Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is SeaStar Medical Holding Corporation Common Stock?

SeaStar Medical Holding Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -2.97.

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Exchange Ticker
NMS (United States) ICU
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 10, 2024 1:25
Jan. 5, 2026 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion